BIOIMAGING

生物成像

• 批准号: 8360240
• 负责人: MICHAEL Douglas BOSKA
• 金额: $ 14.87万
• 依托单位: UNIVERSITY OF NEBRASKA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8360240
• 关键词: Affect; Biodistribution; Biological Assay; Cells; Contrast Media; Development; Disease; Disease Outcome; Disease Progression; Drug Delivery Systems; Drug Kinetics; Funding; Future; Goals; Grant; Image; Kinetics; Label; Magnetic Resonance Imaging; Measures; Methods; Monitor; National Center for Research Resources; Nebraska; Neurons; Outcome; Perfusion; Perfusion Weighted MRI; Pharmaceutical Preparations; Principal Investigator; Research; Research Activity; Research Infrastructure; Resolution; Resources; Source; Spectrum Analysis; Structure; Therapeutic; Treatment Efficacy; United States National Institutes of Health; Water; Weight; base; cost; design; drug efficacy; imaging modality; improved; in vivo; iron oxide; magnetic resonance spectroscopic imaging; nanomaterials; nanomedicine; nanoparticle; neurotoxicity; non-invasive monitor; single photon emission computed tomography; spectroscopic imaging; tumor; uptake

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This core is designed to provide quantitative magnetic resonance imaging (MRI), volume localized spectroscopy (MRS), spectroscopic imaging (MRSI) and single photon emission computed tomography (SPECT) for in-vivo assays of cell and nanomaterial biodistribution and treatment efficacy. Project support includes pharmacokinetic measures of nanomaterial distribution (Projects 1-4), T2* weighted imaging of superparamagnetic iron oxide labeled cells (Project 3) and nanomaterials (alternate method for improved sensitivity and spatial resolution, Projects 1, 3, 4) or SPECT of gamma labeled nanoparticles (Projects 1, 3, 4) and cells (Project 1). Non-invasive monitoring of disease progression and therapeutic outcomes will be provided by observing tumor size using T1 and T2 weighted MRI (Projects 3,4), tumor perfusion using spin tagged perfusion MRI (Project 4), and early determination of drug efficacy by 31P MRS (Future development, Projects 3,4 and future tumor nanomaterial development projects). Monitoring neuronal viability, neurotoxicity, and/or disease progression will be accomplished using quantitative water-suppressed proton magnetic resonance spectroscopic imaging (1H MRSI) (Projects 1, 2, 3). Although the divisions were made to separate the core structures into drug and disease monitoring, the aims are divided based on technical approaches. This was done with the goals of best describing how the core and its significant technical resources will be utilized. Clearly, the abilities to perform SPECT, a variety of quantitative MRI methods, 1H MRSI, and 31P MRS to support broad based research activities in nanomedicine are critical strengths of this proposal. This core will provide abilities to precisely define drug biodistribution, uptake kinetics, provide support for development of new contrast agents based on targeted nanoparticles, and importantly, affects of nanomaterial drug delivery on disease outcomes.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 该核心旨在提供定量磁共振成像 (MRI)、体积局部光谱 (MRS)、光谱成像 (MRSI) 和单光子发射计算机断层扫描 (SPECT)，用于细胞和纳米材料生物分布和治疗效果的体内分析。项目支持包括纳米材料分布的药代动力学测量（项目 1-4）、超顺磁性氧化铁标记细胞的 T2* 加权成像（项目 3）和纳米材料（提高灵敏度和空间分辨率的替代方法，项目 1、3、4）或伽马标记纳米颗粒（项目 1、3、4）和细胞（项目 1）的 SPECT。 将通过使用 T1 和 T2 加权 MRI（项目 3,4）观察肿瘤大小、使用自旋标记灌注 MRI（项目 4）观察肿瘤灌注以及通过 31P MRS 早期确定药物疗效（未来开发、项目 3,4 和未来肿瘤纳米材料开发项目）来提供疾病进展和治疗结果的非侵入性监测。 将使用定量水抑制质子磁共振波谱成像 (1H MRSI) 来监测神经元活力、神经毒性和/或疾病进展（项目 1、2、3）。 虽然核心结构分为药物监测和疾病监测，但目标是根据技术方法划分的。 这样做的目的是最好地描述如何利用核心及其重要的技术资源。 显然，执行 SPECT、各种定量 MRI 方法、1H MRSI 和 31P MRS 以支持纳米医学领域广泛的研究活动的能力是该提案的关键优势。 该核心将提供精确定义药物生物分布、摄取动力学的能力，为基于靶向纳米颗粒的新型造影剂的开发提供支持，更重要的是，纳米材料药物输送对疾病结果的影响。